FDAnews
www.fdanews.com/articles/146553-novartis-sees-positive-phase-iii-data-for-copd-candidate

Novartis Sees Positive Phase III Data for COPD Candidate

May 18, 2012
Novartis’ chronic obstructive pulmonary disease (COPD) candidate bested placebo in improving lung function, symptom relief and quality of life in a Phase III trial, setting it up for a 2014 U.S. filing. NVA237 (glycopyrronium bromide) showed similar efficacy to Boehringer Ingelheim’s Spiriva (OL tiotropium) in patients with moderate to severe COPD, the company said. The FDA approved Spiriva in 2009 to treat exacerbations of COPD.
Drug Industry Daily